Mainz Biomed (NASDAQ:MYNZ – Free Report) – Analysts at HC Wainwright boosted their Q3 2024 EPS estimates for shares of Mainz Biomed in a research note issued to investors on Monday, November 25th. HC Wainwright analyst Y. Chen now expects that the company will post earnings of ($0.11) per share for the quarter, up from their prior forecast of ($0.18). HC Wainwright has a “Neutral” rating on the stock. The consensus estimate for Mainz Biomed’s current full-year earnings is ($0.88) per share. HC Wainwright also issued estimates for Mainz Biomed’s Q4 2024 earnings at ($0.09) EPS and FY2024 earnings at ($0.59) EPS.
Mainz Biomed Stock Performance
Shares of Mainz Biomed stock opened at $0.23 on Wednesday. Mainz Biomed has a 1 year low of $0.19 and a 1 year high of $1.79. The company’s fifty day simple moving average is $0.26 and its 200-day simple moving average is $0.39.
About Mainz Biomed
Mainz Biomed N.V. develops and sells in-vitro diagnostic tests for the early detection of cancer in the United States. The company offers ColoAlert, a colorectal cancer diagnostic molecular genetic stool test. It also develops PancAlert, a stool-based screening test for the detection of pancreatic cancer.
Read More
- Five stocks we like better than Mainz Biomed
- NYSE Stocks Give Investors a Variety of Quality Options
- Cerence Up 155% in 2 Days: SoundHound AI’s Fierce Competitor
- Investing in Construction Stocks
- Why Warren Buffett Is Selling: A Look at His Latest Market Moves
- ESG Stocks, What Investors Should Know
- Why Amazon Shares May Never Trade Below $200 Again
Receive News & Ratings for Mainz Biomed Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mainz Biomed and related companies with MarketBeat.com's FREE daily email newsletter.
